Диссертация (1174276), страница 22
Текст из файла (страница 22)
Cardiol. – 2012. - Vol.110, N 6. – P. 870-876.98. Arentz, T. Arrhythmogenic Atrial Substrate in Persistent Atrial Fibrillation:Relationship to Heart Failure./ T. Arentz , B. Müller-Edenborn, A. Jadidi // JACC Clin.Electrophysiol. – 2018. - Vol. 4, N 1. – P. 97-98.99. Aziz, E.F. Right ventricular dysfunction is a strong predictor of developingatrial fibrillation in acutely decompensated heart failure patients, ACAP-HF dataanalysis / E.F.
Aziz, M. Kukin, F. Javed, et al. // J. Card. Fail. – 2010. - Vol. 16. – P.827-834.100. ACC/AHA/HFSA 2017 Focused Update of the 2013 ACCF/AHA Guidelinefor the Management of Heart Failure. A Report of the American College of Cardiology /American Heart Association Task Force on Clinical Practice Guidelines and the HeartFailure Society of America. C.W. Yancy, M.
Jessup, B. Bozkurt, et al. // Am. Coll.Cardiol. - 2017. – Vol. 70, Issue 6.101. Bell, V. Influence of vascular function and pulsatile hemodynamics oncardiac function / V. Bell, G.F. Mitchell // Curr. Hypertens. Rep. – 2015. - Vol. 17(9). –P. 580.143102. Bernier, M. Atrial arrhythmias in adult patients with right- versus left-sidedcongenital heart disease anomalies / M.
Bernier, A.J. Marelli, L. Pilote, et al. // Am. J.Cardiol. – 2010. - Vol. 106(4). – P. 547-551.103. Berger, R. N-terminal pro-B-type natriuretic peptide-guided, intensivepatient management in addition to multidisciplinary care in chronic heart failure a 3arm, prospective, randomized pilot study / R. Berger, D. Moertl, S.
Peter, et al. // J.Am. Coll. Cardiol. – 2010. - Vol. 55. – P. 645-653.104. Bhatia, R.S. Outcomes in patients with heart failure treated in hospitals withvarying admission rates: population-based cohort study. / R.S. Bhatia, P.C. Austin, T.A.Stukel, et. al. // BMJ Qual. Saf. — 2014. — Vol. 23, N. 12. — P. 981-988.105. Boldanova, T. Impact of history of heart failure on diagnostic and prognosticvalue of BNP: Results from the B-type Natriuretic Peptide for Acute Shortness ofBreath Evaluation (BASEL) Study / T. Boldanova, M.
Noveanu, T. Breidthardt, et al. //Int. J. Cardiol. – 2009. - Vol. 142, N. 3. – P. 265-272.106. Booth, R.A. Performance of BNP and NT-proBNP for diagnosis of heartfailure in primary care patients: a systematic review / R.A. Booth, S.A. Hill, А.DonWauchope, et al. // Heart Fail Rev. – 2014. – Vol. 19. – Р.439–451.107. Buch, P. Reduced lung function and risk of atrial fibrillation in TheCopenhagen City Heart Study / P. Buch, J.
Friberg, H. Scharling, et al. // Eur. Resp. J. –2003. - Vol. 21(6). – P. 1012-1016.108. Camm, A.J. European Heart Rhythm Association. European Association forCardio-Thoracic Surgery Guidelines for the management of atrial fibrillation: The TaskForce for the Management of Atrial Fibrillation of the European Society of Cardiology(ESC) / A.J. Camm, P. Kirchhof, G.Y. Lip, et al. // Eur. Heart J. – 2010. - Vol. 31(19). –P. 2369-2429.109.
Canepa, M. Characteristics, treatments and 1-year prognosis of hospitalizedand ambulatory heart failure patients with chronic obstructive pulmonary disease in theEuropean Society of Cardiology Heart Failure Long-Term Registry / M. Canepa, E.Straburzynska-Migaj, J. Drozdz, et al. // Eur. J. Heart Fail. – 2018. – Vol. 20, N. 1. – Р.100-110.144110. Canepa, M. Prevalence and Prognostic Impact of Chronic ObstructivePulmonary Disease in Patients with Chronic Heart Failure: Data from the GISSI-HFTrial / M.
Canepa, P.L. Temporelli, A. Rossi, et al. // GISSI-HF Investigators.Cardiology. – 2017. – Vol. 136, N. 2. – Р. 128-137.111. Celli, B.R. Inflammatory biomarkers improve clinical prediction of mortalityin chronic obstructive pulmonary disease / B.R. Celli, N. Locantore, J.Yates, et al.
//Am. J. Respir. Crit. Care Med. – 2012. - Vol. 185, N. 10. – P. 1065-1072.112. Chamberlain, A.M. Atrial fibrillation and mortality in heart failure: acommunity study / A.M. Chamberlain, M.M. Redfield, A. Alonso, et al. // Circ. HeartFail. – 2011. - Vol. 4. – P. 740-746.113. Chi, S.Y. Plasma N-terminal Pro-brain Natriuretic Peptide: A prognosticmarker in patients with chronic obstructive pulmonary disease / S.Y. Chi, E.Y. Kim, H.J. Ban, et al.
// Lung. – 2012. – Vol. 190, N. 3. – Р. 271-276.114. Clerico, A. The paradox of low BNP levels in obesity / А. Clerico, А.Giannoni, S. Vittorini, et al. // Heart Fail. Rev. – 2012. – Vol.1. – Р.81–96.115. De Blois, J. COPD predicts mortality in HF: the Norwegian Heart FailureRegistry / J. De Blois, S.
Simard, D. Atar, et al. // J. Card. Fail. – 2010. - Vol. 16. – P.226-229.116. Dharmarajan, K. Epidemiology, pathophysiology, and prognosis of heartfailure in older adults / К. Dharmarajan, М. Rich // Heart Failure Clinics. – 2017. - Vol.13 (3). – Р.417–426.117. Dunlay, S.M. Epidemiology of heart failure with preserved ejection fraction/ S.M.
Dunlay, V.L. Roger, M.M. Redfield // Nature Reviews Cardiology. – 2017. –Vol. 14, N. 10. – Р. 591.118. Duvoix, A. Blood fibrinogen as a biomarker of chronic obstructivepulmonary disease / A. Duvoix, J. Dickens, I. Haq, et al. // Thorax. – 2013. – Vol. 68. –Р. 670-676.119. Duvoix, A. Evaluation of full-length, cleaved and nitrosylated serumsurfactant protein D as biomarkers for COPD / A. Duvoix, E.
Miranda, J. Perez, et al. //COPD – 2011. – Vol. 8, N. 2. – Р. 79-95.145120. Eapen, Z.J. Associations between atrial fibrillation and early outcomes ofpatients with heart failure and reduced or preserved ejection fraction / Z.J. Eapen, M.A.Greiner, G.C. Fonarow, et al. // Am. Heart J. – 2014. – Vol. 167. – Р. 369-375.121. Garin, O. Disease-specific health-related guality of life questionnaires forheart failure: a systematic review with meta-analyses / O.
Garin, M. Ferrer, A. Pont, etal. // Qual. Life Res. – 2009. – Vol. 18. – P. 71-85.122. Garin, O. Evidence on the global measurement model of the MinnesotaLiving with Heart Failure Questionnaire / O. Garin, M. Ferrer, А. Pont, et al. // QualLife Res. – 2013. – Vol. 22, N. 10. – Р. 2675-2684123. Gazewood, J.D. Heart Failure with Preserved Ejection Fraction: Diagnosisand Management / J.D. Gazewood, P.L. Turner // American family physician.
– 2017. –Vol. 96, N. 9. – Р.582-588124. Gigli, L. Clinical characteristics and prognostic impact of atrial fibrillation inpatients with chronic heart failure / L. Gigli, Р. Ameri, G. Secco, et al. // World J.Cardiol. – 2016. – Vol. 8 (11). – Р. 647 - 656.125. Griffo, R. Frequent coexistence of chronic heart failure and chronicobstructive pulmonary disease in respiratory and cardiac outpatients: Evidence fromSUSPIRIUM, a multicentre Italian survey. / R.
Griffo, A. Spanevello, P.L. Temporelli,et al. // Eur J Prev Cardiol. – 2017. – Vol. 24, N. 6. – Р. 567-576.126. Guazzi, M. Endothelial dysfunction and lung capillary injury incardiovascular diseases / M. Guazzi, S.A. Phillips, R. Arena, C.J. Lavie // ProgCardiovasc Dis. – 2015. – Vol.
57, N. 5. – Р. 454-462127. Hage, С. Inflammatory Biomarkers Predict Heart Failure Severity andPrognosis in Patients With Heart Failure With Preserved Ejection Fraction: A HolisticProteomic Approach / C. Hage, E. Michaëlsson, C. Linde, et al. // Circulation:Cardiovascular Genetics. – 2017. – Vol.10, N.1.128. Hawkins, N.M. Chronic obstructive pulmonary disease and heart failure inEurope-further evidence of the need for integrated care / N. M. Hawkins // Eur.
J. HeartFail. – 2018. – Vol. 20, N. 1. – Р. 111-113.146129. Hawkins, N.M. Heart failure and chronic obstructive pulmonary disease: thechallenges facing physicians and health services / N.M. Hawkins, S. Virani, C. Ceconi //Eur. Heart J. – 2013. – Vol. 34, N. 36. – Р. 2795 - 2803.130.
Headenreich, P.A. Forecasting the future of cardiovascular disease in theUnited States: a policy statement from the American Heart Association / P.A.Headenreich, J.G. Trogdon, O.A. Khavjou, et al. // Circulation. – 2011. – Vol. 123, N.8. – Р. 933 - 944.131. Hijazi, Z. Cardiac biomarkers are associated with an increased risk of strokeand death in patients with atrial fibrillation: a Randomized Evaluation of Long-termAnticoagulation Therapy (RE-LY) substudy / Z.
Hijazi, J. Oldgren, U. Andersson, et al.// Circulation. – 2012. – Vol. 125, N. 13. – Р. 1605 - 1616.132. Hill, J. Circulating surfactant protein-D and the risk of cardiovascularmorbidity and mortality / J. Hill, C. Heslop, S.F. Man, et al. // Eur. Heart J.
– 2011. –Vol. 32. – Р. 1918 - 1925.133. Huang, B. Clinical characteristics and prognostic significance of chronicobstructive pulmonary disease in patients with atrial fibrillation: results from amulticenter atrial fibrillation registry study / B. Huang, Y. Yang, J. Zhu, et al. // J. Am.Med. Dir. Assoc. – 2014. - Vol. 15, N.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
